Table 4.
Percentage of Evaluated Patients Without ADT, GI and GU Adverse Effects, PSA Concentration, and Pain Intensity of Evaluated Patients During FU.
| Time After SABR | SABR End | 1 Month | 3 Months | 6 Months | 9 Months | 12 Months | 15 Months | 18 Months | 21 Months | 24 Months | 30 Months | 36 Months | 42 Months | 48 Months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | 38 (100) | 23 (61) | 29 (76) | 27 (71) | 24 (63) | 24 (63) | 13 (34) | 9 (24) | 9 (24) | 9 (24) | 7 (18) | 9 (24) | 9 (24) | 5 (13) |
| Without ADT (%) | 44.7 | 43.5 | 48.3 | 47.8 | 50 (5% CT) | 47.6 (9.5% CT) | 30.8 | 55.6 | 55.6 | 33.3 | 28.6 | 55.6 | 33.3 | 20 |
| GI 0 (%) | 97.4 | 95.5 | 92.6 | 95.7 | 90.4 | 85.7 | 92.3 | 100 | 100 | 100 | 100 | 88.9 | 100 | 100 |
| GI 1 (%) | 2.6 | 4.5 | 7.4 | 4.3 | 4.8 | 9.5 | 7.7 | 11.1 | ||||||
| GI 2 (%) | 4.8 | 4.8 | ||||||||||||
| GI 3 (%) | ||||||||||||||
| GU 0 (%) | 78.9 | 59.1 | 70.4 | 69.6 | 81.0 | 71.4 | 75.0 | 88.9 | 77.8 | 87.5 | 85.7 | 88.9 | 77.8 | 80 |
| GU 1 (%) | 15.8 | 31.8 | 18.5 | 17.4 | 4.8 | 20.8 | 8.3 | 11.1 | 14.3 | 11.1 | 22.2 | 20 | ||
| GU 2 (%) | 5.3 | 9.1 | 7.4 | 13.0 | 9.4 | 4.8 | 16.7 | 11.1 | ||||||
| GU 3 (%) | 3.7 | 4.8 | 11.1 | 12.5 | ||||||||||
| PSA mean | 5.98 | 2.14 | 2.76 | 3.70 | 2.32 | 12.20 | 21.90 | 176.83 | 14.20 | 4.42 | 21.06 | 20.22 | 35.97 | 130.45 |
| PSA median | 3.26 | 0.87 | 0.65 | 0.27 | 0.24 | 0.42 | 1.11 | 1.20 | 1.50 | 0.84 | 0.84 | 1.09 | 2.19 | 0.80 |
| BPI mean | 0.026 | 0.182 | 0.259 | 0.044 | 0.667 | 0.250 | 0.000 | 0.111 | 0.000 | 0.500 | 0.000 | 0.000 | 0.556 | 1.25 |
Abbreviations: ADT, androgen deprivation therapy; BPI, Brief Pain Inventory; CT, chemotherapy; FU, follow-up; GI, gastrointestinal; GU, genitourinary; PSA, prostate-specific antigen; SABR, stereotactic ablative radiotherapy.